really amazing explaination about the phase1 result from the MD tweet!
I think people should easily understand such an excellent result.
Epidyolex make around $600m US dollars sales per year. but there are some disadvantage about epidyolex such as very high cost, it is oil which make people very hard to consume and it is not that stable.
RX5 so far has showed the drug can overcome all the epidyolex disadvantages. I am really happy about the result. I think EMD will have great future.
RX5 is just one of them. also RX7 and other drugs development program.
the market hasn't realize the huge potential of EMD.
really excited about EMD!
- Forums
- ASX - By Stock
- EMD
- Ann: EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial
Ann: EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial, page-44
Featured News
Add EMD (ASX) to my watchlist
|
|||||
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $18.81M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.6¢ | $17.53K | 369.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 490000 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.8¢ | 39900 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 490000 | 0.045 |
1 | 50000 | 0.044 |
1 | 150000 | 0.043 |
2 | 95820 | 0.042 |
2 | 22500 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.048 | 39900 | 1 |
0.050 | 288369 | 4 |
0.055 | 8341 | 1 |
0.058 | 13333 | 1 |
0.060 | 100000 | 1 |
Last trade - 15.12pm 19/06/2024 (20 minute delay) ? |
Featured News
EMD (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online